Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Kidney Case Conference: How I Treat
You have accessRestricted Access

Treatment of Growth Retardation in a Child with CKD

Emily Stonebrook and John D. Mahan
CJASN November 2019, 14 (11) 1658-1660; DOI: https://doi.org/10.2215/CJN.03960319
Emily Stonebrook
Division of Pediatric Nephrology, Department of Pediatrics, Nationwide Children’s Hospital, The Ohio State University College of Medicine, Columbus, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Mahan
Division of Pediatric Nephrology, Department of Pediatrics, Nationwide Children’s Hospital, The Ohio State University College of Medicine, Columbus, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • chronic kidney disease
  • children
  • growth
  • nutrition
  • growth hormone therapy
  • child
  • humans
  • developmental disabilities
  • Endocrine System Diseases
  • Infant, Newborn, Diseases
  • Renal Insufficiency, Chronic
  • Infant, Newborn

Introduction

Growth failure in children with CKD is a common and important problem. Short stature at the time of dialysis initiation is an independent predictor of poor outcomes, including increased hospitalization and mortality rates (1). In addition, children with CKD rank growth as a high priority, especially as they approach adolescence (2). Moreover, adults with CKD as children who achieve greater final adult height describe better quality of life (3). Early intervention is important for best growth outcomes.

Case 1

  • NJ is a 3.5-year-old girl diagnosed with cystinosis and has CKD stage 3. At diagnosis, the patient’s weight is 12.7 kg (9.72%, Z=−1.3) and height is 88.8 cm (1.87%, Z=−2.08).

Clinical Question: What Is the Significance of Weight and Height SD Scores When Assessing Growth?

It is important to determine height, weight, and body mass index for age as percentiles or SD scores (SDS; SDs from the predicted mean for age) (4). A prime issue in assessing a child with CKD with poor growth is whether adequate nutrition is being achieved. Comparing height and weight SDS, and trends, can provide valuable insights. If the weight SDS is equal to or less than the height SDS, protein and calorie intake should be investigated. Similarly, if weight SDS decreases more rapidly than height SDS over time, or fails to improve as quickly as height SDS with interventions, this suggests insufficient nutrition.

Normalized protein catabolic rate is a measure of dietary protein intake and nutrition status in patients on maintenance hemodialysis, with goal ≥1.0. It is a better marker of protein intake than serum albumin, which can be affected by other factors, including acidosis, inflammation, infection, etc.

  • By 5 years of age, NJ’s weight is 14.9 kg (8.78%, Z=−1.38) and height is 95.3 cm (0.18%, Z=−2.91). Although her weight SDS has remained stable, her height SDS has decreased over time. This suggests that inadequate nutrition is not the primary culprit of her poor growth.

Clinical Question: What Are the Typical Barriers to Growth in CKD?

Many factors can contribute to poor growth in children with CKD. Some of these factors are non-modifiable, including age of onset of CKD, underlying primary kidney disease, severity of kidney insufficiency, and genetic factors (5). Generally, younger children and those with more advanced CKD struggle most with growth.

CKD creates multiple additional barriers to growth (Figure 1). CKD related metabolic acidosis is associated with growth hormone (GH) resistance and enhanced calcium efflux from bone (6). Water, electrolyte, and mineral losses can cause abnormalities of sodium, potassium, calcium, and/or phosphate, which impair growth (7).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Barriers to achieving progrowth state in children with CKD. Both modifiable factors such as nutrition and metabolic bone disease, and nonmodifiable factors like inflammation contribute to poor growth. Each of these barriers must be addressed by the family and interdisciplinary team to optimize conditions for a progrowth state.

Secondary hyperparathyroidism leads to metabolic bone disease and affects skeletal growth and remodeling. However, oversuppression of parathyroid hormone (PTH) levels can lead to osteomalacia and a low-turnover state (adynamic bone disease) (8). Inflammation interacts with uremia to decrease appetite and can further impair calorie and protein intake.

In CKD, the GH–IGF-1 axis is abnormal because of both resistance to GH at the cellular level and accumulation of IGF-1 binding protein. This frequently results in suboptimal growth, despite “normal” serum GH (7).

  • NJ is started on recombinant human growth hormone (rhGH) injections and grows 8 cm over 6 months. NJ’s weight is now 16.1 kg (5.87%, Z=−1.57) and height is 103.3 cm (2.07%, Z=−2.04). Her height SDS improved, her weight SDS remained stable, and caloric and protein intake was below goal.

Clinical Question: What Nutritional Approaches Are There to CKD Management in Children?

Nutritional assessments should be performed as often as monthly on children with CKD including anthropometric parameters and dietary records. The dietician plays a significant role in monitoring parameters, identifying issues, and enacting appropriate interventions.

Children with CKD stages 2–5 should receive 100% of their estimated energy requirements (EER), adjusted for physical activity and body mass index (4). This should then be adjusted to achieve desired rate of weight gain. Protein intake recommendations vary depending on stage of CKD, ranging from 100% to 140% of dietary reference intake for ideal body weight. Children with CKD often have decreased appetite, abnormal taste, and early satiety, making it difficult to meet goals (6). If necessary, supplemental nutrition should be provided. Oral supplements, appetite stimulants, and nasogastric or gastric tube (G-tube) feeds may be required.

  • NJ had a G-tube placed and a balanced pediatric supplemental feed was initiated. Weight subsequently improved and is now stable at the 30th–40th percentile, with excellent growth with G-tube supplementation and rhGH administration.

Case 2

  • JT is a 7-year-old boy with obstructive uropathy and failed deceased donor transplant due to medication nonadherence, now resuming maintenance intermittent hemodialysis. His weight is 23.9 kg (54.16%, Z=0.10) and height is 118.1 cm (19.25%, Z=−0.87). His medications include amlodipine, B complex with folic acid, calcium carbonate, cholecalciferol, epoetin α, and omeprazole. He is on a low phosphorus diet. His intact PTH is 1063 pg/ml.

Clinical Question: How Do You Approach Medical Management of Barriers to Growth?

While nutrition is being optimized, any other modifiable factors that impair a progrowth state should be addressed (Figure 1). Patients with acidosis should receive alkali therapy or adjustment of their dialysis prescription to maintain serum bicarbonate levels >22 mmol/L (6). Electrolyte problems can be addressed by dietary modifications, phosphate or potassium binders, and/or alteration of dialysis prescription. Target intact PTH should be <900 pg/ml in a child with CKD stage 5, or <400 pg/ml in CKD stages 2–4 (4). Synthetic vitamin D analogs, vitamin D receptor agonists, or calcimimetics should be used to maintain PTH within goal range. Children on dialysis should have routine assessments of dialysis adequacy.

  • JT is started on paricalcitol with improvement of PTH to 188 pg/ml. Six months later, his weight is 27.6 kg (74.32%, Z=0.65) and height is 118 cm (7.54%, Z= −1.44). rhGH is started because of his worsening height SDS, and he grows 9 cm over the next year, with appropriate weight gain.

Clinical Question: How Should Children with CKD Be Started and Subsequently Managed on rhGH?

The CKD GH resistance state can be overcome by achieving supraphysiologic GH levels through exogenous rhGH therapy (9). Modifiable factors should be successfully addressed for 3–4 months, and then, if minimal or no improvement in growth velocity or height SDS, rhGH should be started (5). Thyroid studies, hip and knee radiographs, bone age, and fundoscopic examination should be performed before rhGH initiation (6).

rhGH starting dose is 0.05 mg/kg per day by subcutaneous injection. For patients on dialysis, injections should be timed to minimize clearance: given 3–4 hours after hemodialysis completion, or during longest dwell for peritoneal dialysis patients [10].

Growth should be reassessed every 3–4 months (5). For children with CKD stages 2–4, the goal is for growth of 7–20 cm per year; a lesser response is expected for children on dialysis. If the child grows <2 cm more than the previous year (when not on rhGH) then re-evaluation for other potential modifiable risk factors is important (8). Dose adjustment for weight gain is also necessary [10]. Monitoring for potential rhGH side effects, including mild hyperglycemia, intracranial hypertension, and slipped capital femoral epiphysis, is important (5).

Good growth is the best outcome for the child with CKD, and must be the primary goal for the family and the health care team.

Lay Summary

Growth failure in children with CKD is a common and important problem, from the view of the physician, patient, and family. Short stature and poor growth is associated with poor outcomes, including increased medical problems and increased death rates in affected children. Early intervention is critical for successful growth, with inadequate nutrition being the most likely concern. A number of other medical issues must be addressed to promote best growth in these children and daily GH injections may be required to obtain good growth in children with CKD. Adults who had CKD as children who achieve greater final adult height have better quality of life and achieve higher education levels, increased employment rates, more successful marriages, and increased rates of independent living as adults.

Disclosures

Dr. Mahan reports personal fees outside the submitted work from the American Academy of Pediatrics, Pedialink, Relypsa, and Vifor. Dr. Stonebrook has nothing to disclose.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2019 by the American Society of Nephrology

References

  1. ↵
    1. Furth SL,
    2. Hwang W,
    3. Yang C,
    4. Neu AM,
    5. Fivush BA,
    6. Powe NR
    : Growth failure, risk of hospitalization and death for children with end-stage renal disease. Pediatr Nephrol 17: 450–455, 2002
    OpenUrlCrossRefPubMed
  2. ↵
    1. Postlethwaite RJ,
    2. Eminson DM,
    3. Reynolds JM,
    4. Wood AJ,
    5. Hollis S
    : Growth in renal failure: A longitudinal study of emotional and behavioural changes during trials of growth hormone treatment. Arch Dis Child 78: 222–229, 1998
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Broyer M,
    2. Le Bihan C,
    3. Charbit M,
    4. Guest G,
    5. Tete MJ,
    6. Gagnadoux MF,
    7. Niaudet P
    : Long-term social outcome of children after kidney transplantation. Transplantation 77: 1033–1037, 2004
    OpenUrlCrossRefPubMed
  4. ↵
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011) 7: 1–59, 2017
  5. ↵
    1. Mahan JD,
    2. Warady BA
    ; Consensus Committee: Assessment and treatment of short stature in pediatric patients with chronic kidney disease: A consensus statement. Pediatr Nephrol 21: 917–930, 2006
    OpenUrlCrossRefPubMed
  6. ↵
    1. Mehrotra R,
    2. Kopple JD,
    3. Wolfson M
    : Metabolic acidosis in maintenance dialysis patients: Clinical considerations. Kidney Int Suppl (88): S13–S25, 2003
  7. ↵
    1. Janjua HS,
    2. Mahan JD
    : Growth in chronic kidney disease. Adv Chronic Kidney Dis 18: 324–331, 2011
    OpenUrlCrossRefPubMed
  8. ↵
    1. Wesseling K,
    2. Bakkaloglu S,
    3. Salusky I
    : Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol 23: 195–207, 2008
    OpenUrlCrossRefPubMed
  9. ↵
    1. Tönshoff B,
    2. Fine RN
    : Recombinant human growth hormone for children with renal failure. Adv Ren Replace Ther 3: 37–47, 1996
    OpenUrlPubMed
  10. ↵
    1. Rees L
    : Growth hormone therapy in children with CKD after more than two decades of practice. Pediatr Nephrol 31: 1421–1435, 2016
    OpenUrl
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 14 (11)
Clinical Journal of the American Society of Nephrology
Vol. 14, Issue 11
November 07, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Treatment of Growth Retardation in a Child with CKD
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Treatment of Growth Retardation in a Child with CKD
Emily Stonebrook, John D. Mahan
CJASN Nov 2019, 14 (11) 1658-1660; DOI: 10.2215/CJN.03960319

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Treatment of Growth Retardation in a Child with CKD
Emily Stonebrook, John D. Mahan
CJASN Nov 2019, 14 (11) 1658-1660; DOI: 10.2215/CJN.03960319
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Introduction
    • Case 1
    • Case 2
    • Lay Summary
    • Disclosures
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Walkaway PIRRT (as SLED) for Acute Kidney Injury
  • How We Manage Hypertension in a Patient with a Recent Stroke
  • Secondary Hyperparathyroidism in a Patient with CKD
Show more Kidney Case Conference: How I Treat

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Keywords

  • chronic kidney disease
  • children
  • growth
  • nutrition
  • growth hormone therapy
  • child
  • Humans
  • developmental disabilities
  • Endocrine System Diseases
  • Infant, Newborn, Diseases
  • renal insufficiency, chronic
  • Infant, Newborn

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire